STADA & Bio-Thera bag European nod for Gotenfia

Lyell Immunopharma launches groundbreaking Phase 3 CAR T-Cell trial for aggressive lymphoma

PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma

FDA nod to Acrotech's new eczema treatment

ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis

Fortis Healthcare posts strong Q3 FY26 growth; revenues up 17.5% YoY

The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore

FDA refuses to file Moderna’s seasonal flu vaccine application, citing comparator issue

The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”

Precision BioSciences cleared by FDA to launch groundbreaking Duchenne gene editing trial

PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients

BioAsia 2026 positions Telangana as a global TechBio powerhouse

BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem

Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer

KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components

Alkem MedTech to acquire 55% stake in Switzerland's Occlutech for €99.4M

Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure

Syngene collaborates with Johns Hopkins University to advance early-stage drug discovery

The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research